CD4 and nasopharyngeal carcinoma: A CD4+ T cell receptor specific to HLA-DP5-restricted EBNA1567-581, provides a strategy for Epstein-Barr virus-related nasopharyngeal cancer immunotherapy in HLA-DP5+ patients.